The DOI matches its Crossref record; 129 of the 129 references it cites were found in a registry or an index.
Parkinson’s Disease: From Pathogenesis to Pharmacogenomics
Open accessAbstract
Parkinson’s disease (PD) is the second most important age-related neurodegenerative disorder in developed societies, after Alzheimer’s disease, with a prevalence ranging from 41 per 100,000 in the fourth decade of life to over 1900 per 100,000 in people over 80 years of age. As a movement disorder, the PD phenotype is characterized by rigidity, resting tremor, and bradykinesia. Parkinson’s disease -related neurodegeneration is likely to occur several decades before the onset of the motor symptoms. Potential risk factors include environmental toxins, drugs, pesticides, brain microtrauma, focal cerebrovascular damage, and genomic defects. Parkinson’s disease neuropathology is characterized by a selective loss of dopaminergic neurons in the substantia nigra pars compacta, with widespread involvement of other central nervous system (CNS) structures and peripheral tissues. Pathogenic mechanisms associated with genomic, epigenetic and environmental factors lead to conformational changes and deposits of key proteins due to abnormalities in the ubiquitin–proteasome system together with dysregulation of mitochondrial function and oxidative stress. Conventional pharmacological treatments for PD are dopamine precursors (levodopa, l-DOPA, l-3,4 dihidroxifenilalanina), and other symptomatic treatments including dopamine agonists (amantadine, apomorphine, bromocriptine, cabergoline, lisuride, pergolide, pramipexole, ropinirole, rotigotine), monoamine oxidase (MAO) inhibitors (selegiline, rasagiline), and catechol-O-methyltransferase (COMT) inhibitors (entacapone, tolcapone). The chronic administration of antiparkinsonian drugs currently induces the “wearing-off phenomenon”, with additional psychomotor and autonomic complications. In order to minimize these clinical complications, novel compounds have been developed. Novel drugs and bioproducts for the treatment of PD should address dopaminergic neuroprotection to reduce premature neurodegeneration in addition to enhancing dopaminergic neurotransmission. Since biochemical changes and therapeutic outcomes are highly dependent upon the genomic profiles of PD patients, personalized treatments should rely on pharmacogenetic procedures to optimize therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The prevalence of Parkinson's disease: a systematic review and meta-analysis
Pringsheim, T., Jette, N., Frolkis, A., & Steeves, T. D. L. (2014) · Movement Disorders · doi:10.1002/mds.25945 · Cited by 2,188
International Parkinson's Disease Genomics Consortium (IPDGC), Nalls, M. A., Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI), 23andMe, GenePD, NeuroGenetics Research Consortium (NGRC), Hussman Institute of Human Genomics (HIHG), Investigator, T. A. J. D., (CHARGE), C. F. H. A. A. R. I. G. E., North American Brain Expression Consortium (NABEC), et al. (2014) · Nature Genetics · doi:10.1038/ng.3043 · Cited by 1,895 · cited 1×
“Replication studies confirmed 24 single nucleotide polymorphisms (SNPs), and conditional analyses within loci showed four loci —β-Glucocerebrosidase (GBA); Diacylglycerol kinase θ, 110kD (GAK-DGKQ); SNCA; Human leukocyte antigen (HLA)—with a secondary independent risk variant [52].”
BackgroundToledo, J. B., Arnold, S. E., Raible, K., Brettschneider, J., Xie, S. X., Grossman, M., Monsell, S. E., Kukull, W. A., & Trojanowski, J. Q. (2013) · Brain · doi:10.1093/brain/awt188 · Cited by 849
Mitochondrial dysfunction in Parkinson's disease
Bose, A., & Beal, M. F. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13731 · Cited by 841
Neurotransmitters: The Critical Modulators Regulating Gut–Brain Axis
Mittal, R., Debs, L. H., Patel, A. P., Nguyen, D., Patel, K., O'Connor, G., Grati, M., Mittal, J., Yan, D., Eshraghi, A. A., et al. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25518 · Cited by 636
Prevalence and incidence of Parkinson's disease in Europe
von Campenhausen, S., Bornschein, B., Wick, R., Bötzel, K., Sampaio, C., Poewe, W., Oertel, W., Siebert, U., Berger, K., & Dodel, R. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.04.007 · Cited by 625
Irwin, D. J., Grossman, M., Weintraub, D., Hurtig, H. I., Duda, J. E., Xie, S. X., Lee, E. B., Van Deerlin, V. M., Lopez, O. L., Kofler, J. K., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30291-5 · Cited by 588
The Incidence of Parkinson's Disease: A Systematic Review and Meta-Analysis
Hirsch, L., Jette, N., Frolkis, A., Steeves, T., & Pringsheim, T. (2016) · Neuroepidemiology · doi:10.1159/000445751 · Cited by 571
Nuytemans, K., Theuns, J., Cruts, M., & Van Broeckhoven, C. (2010) · Human Mutation · doi:10.1002/humu.21277 · Cited by 563
Lill, C. M., Roehr, J. T., McQueen, M. B., Kavvoura, F. K., Bagade, S., Schjeide, B.-M. M., Schjeide, L. M., Meissner, E., Zauft, U., Allen, N. C., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002548 · Cited by 529
Do, C. B., Tung, J. Y., Dorfman, E., Kiefer, A. K., Drabant, E. M., Francke, U., Mountain, J. L., Goldman, S. M., Tanner, C. M., Langston, J. W., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002141 · Cited by 515
Edwards, T. L., Scott, W. K., Almonte, C., Burt, A., Powell, E. H., Beecham, G. W., Wang, L., Züchner, S., Konidari, I., Wang, G., et al. (2010) · Annals of Human Genetics · doi:10.1111/j.1469-1809.2009.00560.x · Cited by 465
Genetics in Parkinson disease: Mendelian versus non‐Mendelian inheritance
Hernandez, D. G., Reed, X., & Singleton, A. B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13593 · Cited by 448
Genomewide association study for susceptibility genes contributing to familial Parkinson disease
Pankratz, N., Wilk, J. B., Latourelle, J. C., DeStefano, A. L., Halter, C., Pugh, E. W., Doheny, K. F., Gusella, J. F., Nichols, W. C., Foroud, T., et al. (2009) · Human Genetics · doi:10.1007/s00439-008-0582-9 · Cited by 443
Parkinson's Disease and Alpha Synuclein: Is Parkinson's Disease a Prion‐Like Disorder?
Olanow, C. W., & Brundin, P. (2013) · Movement Disorders · doi:10.1002/mds.25373 · Cited by 390
Striatal dopamine neurotransmission: Regulation of release and uptake
Sulzer, D., Cragg, S. J., & Rice, M. E. (2016) · Basal Ganglia · doi:10.1016/j.baga.2016.02.001 · Cited by 382
The epigenetics of aging and neurodegeneration
Lardenoije, R., Iatrou, A., Kenis, G., Kompotis, K., Steinbusch, H. W. M., Mastroeni, D., Coleman, P., Lemere, C. A., Hof, P. R., van den Hove, D. L. A., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.05.002 · Cited by 381
Current and experimental treatments of Parkinson disease: A guide for neuroscientists
Oertel, W., & Schulz, J. B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13750 · Cited by 369
Genetics of Parkinson's disease
Lill, C. M. (2016) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2016.11.001 · Cited by 361
Biomarkers of Parkinson’s disease: Present and future
Miller, D. B., & O’Callaghan, J. P. (2015) · Metabolism · doi:10.1016/j.metabol.2014.10.030 · Cited by 358
Funayama, M., Ohe, K., Amo, T., Furuya, N., Yamaguchi, J., Saiki, S., Li, Y., Ogaki, K., Ando, M., Yoshino, H., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70266-2 · Cited by 351
Jellinger, K. A. (1999) · Journal of Neural Transmission. Supplementa · doi:10.1007/978-3-7091-6360-3_1 · Cited by 347
Masliah, E., Dumaop, W., Galasko, D., & Desplats, P. (2013) · Epigenetics · doi:10.4161/epi.25865 · Cited by 319
Cardiovascular dysautonomia in Parkinson disease: From pathophysiology to pathogenesis
Jain, S., & Goldstein, D. S. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.10.025 · Cited by 297
Meta‐analysis of Parkinson's Disease: Identification of a novel locus, RIT2
Pankratz, N., Beecham, G. W., DeStefano, A. L., Dawson, T. M., Doheny, K. F., Factor, S. A., Hamza, T. H., Hung, A. Y., Hyman, B. T., Ivinson, A. J., et al. (2012) · Annals of Neurology · doi:10.1002/ana.22687 · Cited by 285
Time Trends in the Incidence of Parkinson Disease
Savica, R., Grossardt, B. R., Bower, J. H., Ahlskog, J. E., & Rocca, W. A. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0947 · Cited by 270
Norepinephrine: The redheaded stepchild of Parkinson's disease
Rommelfanger, K. S., & Weinshenker, D. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.01.036 · Cited by 255
Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis
Moisan, F., Kab, S., Mohamed, F., Canonico, M., Le Guern, M., Quintin, C., Carcaillon, L., Nicolau, J., Duport, N., Singh-Manoux, A., et al. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-312283 · Cited by 244
Norepinephrine deficiency in Parkinson's disease: The case for noradrenergic enhancement
Espay, A. J., LeWitt, P. A., & Kaufmann, H. (2014) · Movement Disorders · doi:10.1002/mds.26048 · Cited by 234
Cenci, M. A. (2014) · Frontiers in Neurology · doi:10.3389/fneur.2014.00242 · Cited by 233
The relationship between glucocerebrosidase mutations and Parkinson disease
Migdalska‐Richards, A., & Schapira, A. H. V. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13385 · Cited by 231
Progress in unraveling the genetic etiology of Parkinson disease in a genomic era
Verstraeten, A., Theuns, J., & Van Broeckhoven, C. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.01.004 · Cited by 226
Treatment of Parkinson's disease: levodopa as the first choice
Katzenschlager, R., & Lees, A. J. (2002) · Journal of Neurology · doi:10.1007/s00415-002-1204-4 · Cited by 209
Lohr, K. M., Bernstein, A. I., Stout, K. A., Dunn, A. R., Lazo, C. R., Alter, S. P., Wang, M., Li, Y., Fan, X., Hess, E. J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402134111 · Cited by 209
Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease
Buddhala, C., Loftin, S. K., Kuley, B. M., Cairns, N. J., Campbell, M. C., Perlmutter, J. S., & Kotzbauer, P. T. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.246 · Cited by 206
Xing, B., Li, Y.-C., & Gao, W.-J. (2016) · Brain Research · doi:10.1016/j.brainres.2016.01.005 · Cited by 196
Systematic review of the prevalence and incidence of Parkinson's disease in Asia
Muangpaisan, W., Hori, H., & Brayne, C. (2009) · Journal of Epidemiology · doi:10.2188/jea.je20081034 · Cited by 185
Biochemistry of postmortem brains in Parkinson’s disease: historical overview and future prospects
Nagatsu, T., & Sawada, M. (2007) · Neuropsychiatric Disorders An Integrative Approach · doi:10.1007/978-3-211-73574-9_14 · Cited by 184
Constipation in parkinson's disease: Subjective symptoms, objective markers, and new perspectives
Knudsen, K., Krogh, K., Østergaard, K., & Borghammer, P. (2017) · Movement Disorders · doi:10.1002/mds.26866 · Cited by 183
Genome-wide association study confirms extant PD risk loci among the Dutch
Simón-Sánchez, J., van Hilten, J. J., van de Warrenburg, B., Post, B., Berendse, H. W., Arepalli, S., Hernandez, D. G., de Bie, R. M. A., Velseboer, D., Scheffer, H., et al. (2011) · European Journal of Human Genetics · doi:10.1038/ejhg.2010.254 · Cited by 181
Feinstein, D. L., Kalinin, S., & Braun, D. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13447 · Cited by 176
Genetics and Epigenetics of Parkinson's Disease
Coppedè, F. (2012) · The Scientific World Journal · doi:10.1100/2012/489830 · Cited by 175
Identification of TMEM230 mutations in familial Parkinson's disease
Deng, H.-X., Shi, Y., Yang, Y., Ahmeti, K. B., Miller, N., Huang, C., Cheng, L., Zhai, H., Deng, S., Nuytemans, K., et al. (2016) · Nature Genetics · doi:10.1038/ng.3589 · Cited by 172
Liu, X., Cheng, R., Verbitsky, M., Kisselev, S., Browne, A., Mejia-Sanatana, H., Louis, E. D., Cote, L. J., Andrews, H., Waters, C., et al. (2011) · BMC Medical Genetics · doi:10.1186/1471-2350-12-104 · Cited by 168
Chandler, D. J., Waterhouse, B. D., & Gao, W. (2014) · Frontiers in Neural Circuits · doi:10.3389/fncir.2014.00053 · Cited by 157
Of Pesticides and Men: a California Story of Genes and Environment in Parkinson’s Disease
Ritz, B. R., Paul, K. C., & Bronstein, J. M. (2016) · Current Environmental Health Reports · doi:10.1007/s40572-016-0083-2 · Cited by 157
Epigenetics of Aging and Alzheimer’s Disease: Implications for Pharmacogenomics and Drug Response
Cacabelos, R., & Torrellas, C. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226236 · Cited by 152
Self-citationMembrane transporters as mediators of synaptic dopamine dynamics: implications for disease
Lohr, K. M., Masoud, S. T., Salahpour, A., & Miller, G. W. (2016) · European Journal of Neuroscience · doi:10.1111/ejn.13357 · Cited by 140
Wen, K., Milić, J., El‐Khodor, B. F., Dhana, K., Nano, J., Pulido, T., Kraja, B., Začiragić, A., Bramer, W. M., Troup, J., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167201 · Cited by 137
Vermeiren, Y., & Deyn, P. P. D. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.11.009 · Cited by 134
Parkinson's disease correlates with promoter methylation in the α‐synuclein gene
Pihlstrøm, L., Berge‐Seidl, V., Rengmark, A. H., & Toft, M. (2014) · Movement Disorders · doi:10.1002/mds.26073 · Cited by 127
Genetics of Parkinson’s Disease
Singleton, A., & Clarimón, J. (2007) · CRC Press eBooks · doi:10.3109/9781420019223-5 · Cited by 124
Genome-wide association study of Parkinson’s disease in East Asians
Foo, J. N., Tan, L. C. S., Irwan, I. D., Au, W., Low, H. Q., Prakash, K., Ahmad‐Annuar, A., Bei, J., Chan, A. Y. Y., Chen, C., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw379 · Cited by 124
Kimber, J., Watson, L. P. E., & Mathias, C. J. (1997) · The Lancet · doi:10.1016/s0140-6736(96)10168-9 · Cited by 119
Nagatsu, T., & Nagatsu, I. (2016) · Journal of Neural Transmission · doi:10.1007/s00702-016-1596-4 · Cited by 118
New treatments for levodopa‐induced motor complications
Rascol, O., Perez‐Lloret, S., & Ferreira, J. J. (2015) · Movement Disorders · doi:10.1002/mds.26362 · Cited by 113
Levodopa-related wearing-off in Parkinson's disease: identification and management
Pahwa, R., & Lyons, K. E. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902779319 · Cited by 113
Willis, G. L. (2008) · Reviews in the Neurosciences · doi:10.1515/revneuro.2008.19.4-5.245 · Cited by 104
Stowe, R. L., Ives, N. J., Clarke, C. E., Deane, K. H., van Hilten, Wheatley, K., Gray, R. G., Handley, K., & Furmston, A. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007166.pub2 · Cited by 103
Levodopa: Effect on cell death and the natural history of Parkinson's disease
Olanow, C. W. (2014) · Movement Disorders · doi:10.1002/mds.26119 · Cited by 99
Epigenetic drug discovery for Alzheimer’s disease
Cacabelos, R., & Torrellas, C. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.930124 · Cited by 96
Self-citationKaidery, N. A., Tarannum, S., & Thomas, B. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0211-8 · Cited by 93
Parkin Regulation and Neurodegenerative Disorders
Zhang, C., Hang, L., Yao, T., & Lim, K. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00248 · Cited by 92
Epigenome-Wide Association Study for Parkinson’s Disease
Moore, K., McKnight, A. J., Craig, D., & O’Neill, F. A. (2014) · NeuroMolecular Medicine · doi:10.1007/s12017-014-8332-8 · Cited by 91
Pharmacogenomics of Alzheimer’s Disease: Novel Therapeutic Strategies for Drug Development
Cacabelos, R., Cacabelos, P., Torrellas, C., Tellado, I., & Carril, J. C. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0956-8_13 · Cited by 90
Self-citationGenetics of SynucleinopathiesPreprint
Nussbaum, R. L. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024109 · Cited by 85
Rieck, M., Schuh, A. F. S., Altmann, V., Francisconi, C. L. M., Fagundes, P. T., Monte, T. L., Callegari-Jacques, S. M., Rieder, C. R. D. M., & Hutz, M. H. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.149 · Cited by 83
Role of neurotoxicants and traumatic brain injury in α-synuclein protein misfolding and aggregation
Rokad, D., Ghaisas, S., Harischandra, D. S., Jin, H., Anantharam, V., Kanthasamy, A., & Kanthasamy, A. G. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.12.003 · Cited by 81
Xie, Y., Feng, H., Peng, S., Xiao, J., & Zhang, J. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.11.007 · Cited by 79
Wakamatsu, K., Tabuchi, K., Ojika, M., Zucca, F. A., Zecca, L., & Ito, S. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13237 · Cited by 76
Moreau, C., Meguig, S., Corvol, J., Labreuche, J., Vasseur, F., Duhamel, A., Delval, A., Bardyn, T., Devedjian, J.-C., Rouaix, N., et al. (2015) · Brain · doi:10.1093/brain/awv063 · Cited by 69
Monoamine transporters: insights from molecular dynamics simulations
Grouleff, J., Ladefoged, L. K., Koldsø, H., & Schiøtt, B. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00235 · Cited by 68
Riedel, O., Bitters, D., Amann, U., Garbe, E., & Langner, I. (2016) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4414 · Cited by 64
Specificity and impact of adrenergic projections to the midbrain dopamine system
Mejías-Aponte, C. A. (2016) · Brain Research · doi:10.1016/j.brainres.2016.01.036 · Cited by 64
MicroRNA expressing profiles in A53T mutant alpha-synuclein transgenic mice and Parkinsonian
Mo, M., Xiao, Y., Huang, S., Cen, L., Chen, X. '., Zhang, L., Luo, Q., Li, S., Yang, X., Lin, X. Z., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13905 · Cited by 64
Oxidative Modification and Its Implications for the Neurodegeneration of Parkinson’s Disease
Zhao, J., Yu, S., Zheng, Y., Yang, H., & Zhang, J. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9743-3 · Cited by 62
Guidelines for dementia or Parkinson’s disease with depression or anxiety: a systematic review
Goodarzi, Z., Mele, B., Guo, S., Hanson, H. M., Jetté, N., Patten, S. B., Pringsheim, T. M., & Holroyd-Leduc, J. M. (2016) · BMC Neurology · doi:10.1186/s12883-016-0754-5 · Cited by 62
Noradrenergic Regulation of Glial Activation: Molecular Mechanisms and Therapeutic Implications
Braun, D. J., Madrigal, J. L. M., & Feinstein, D. L. (2014) · Current Neuropharmacology · doi:10.2174/1570159x12666140828220938 · Cited by 61
LRRK2 deficiency impacts ceramide metabolism in brain
Ferrazza, R., Cogo, S., Melrose, H. L., Bubacco, L., Greggio, E., Guella, G., Civiero, L., & Plotegher, N. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.08.082 · Cited by 61
Prolactin and sex hormones levels in males with Parkinson's disease
Nitkowska, M., Tomasiuk, R., Czyżyk, M., & Friedman, A. (2014) · Acta Neurologica Scandinavica · doi:10.1111/ane.12334 · Cited by 60
Kleinknecht, A., Popova, B., Lázaro, D. F., Pinho, R., Valerius, O., Outeiro, T. F., & Braus, G. H. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1006098 · Cited by 58
Pharmacogenetic Considerations in the Treatment of Alzheimer’s Disease
Cacabelos, R., Torrellas, C., Teijido, Ó., & Carril, J. C. (2016) · Pharmacogenomics · doi:10.2217/pgs-2016-0031 · Cited by 54
Self-citationScheffold, A., Holtman, I. R., Dieni, S., Brouwer, N., Katz, S.-F., Jebaraj, B. M. C., Kahle, P. J., Hengerer, B., Lechel, A., Stilgenbauer, S., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0364-x · Cited by 53 · cited 1×
“Telomere shortening as a result of the inability to fully replicate the ends of linear chromosomes is one of the hallmarks of aging which might also contribute to PD pathology [31].”
BackgroundThe biomarkers of immune dysregulation and inflammation response in Parkinson disease
Chen, L., Mo, M., Li, G., Cen, L., Wei, L., Xiao, Y., Chen, X., Li, S., Yang, X., Qu, S., et al. (2016) · Translational Neurodegeneration · doi:10.1186/s40035-016-0063-3 · Cited by 53
Identification of genetic modifiers of age-at-onset for familial Parkinson’s disease
Hill‐Burns, E. M., Ross, O. A., Wissemann, W. T., Soto‐Ortolaza, A. I., Zareparsi, S., Siuda, J. S., Lynch, T., Wszołek, Z. K., Silburn, P. A., Mellick, G. D., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw206 · Cited by 52
Teixeira, F. R., Randle, S. J., Patel, S. P., Mevissen, T. E. T., Zenkevičiūtė, G., Koide, T., Komander, D., & Laman, H. (2016) · Biochemical Journal · doi:10.1042/bcj20160387 · Cited by 52
Zou, Y., Liu, J., Tian, Z., Lu, D.-Y., & Zhou, Y. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s85380 · Cited by 51
Gruszka, A., Ren, S.-G., Dong, J. Z., Culler, M. D., & Melmed, S. K. (2007) · Endocrinology · doi:10.1210/en.2007-0378 · Cited by 50
Cardiac parasympathetic dysfunction in the early phase of Parkinson’s disease
Suzuki, M., Nakamura, T., Hirayama, M., Ueda, M. U., Katsuno, M., & Sobue, G. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8348-0 · Cited by 49
Tran, T., Brophy, J. M., Suissa, S., & Renoux, C. (2015) · CNS Drugs · doi:10.1007/s40263-015-0293-4 · Cited by 48
Diurnal Secretion Profiles of Growth Hormone, Thyrotrophin and Prolactin in Parkinson’s Disease
Aziz, N. A., Pijl, H., Frölich, M. A., Roelfsema, F., & Roos, R. A. C. (2011) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2011.02134.x · Cited by 45
Saito, Y., Ogawa, Y., Matsumura, A., Saigoh, K., Itoh, S., Sutou, K., Kobayashi, M., Mita, Y., Shichiri, M., Hisahara, S., et al. (2016) · Scientific Reports · doi:10.1038/srep30793 · Cited by 44
LRRK2 interferes with aggresome formation for autophagic clearance
Bang, Y., Kim, K., Seol, W., & Choi, H. J. (2016) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2016.06.007 · Cited by 42
Naughton, C., O’Toole, D. P., Kirik, D., & Dowd, E. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.08.056 · Cited by 42
Role of the VPS35 D620N mutation in Parkinson's disease
Mohan, M., & Mellick, G. D. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.12.001 · Cited by 40
Rieck, M., Schuh, A. F. S., Callegari-Jacques, S. M., Altmann, V., Medeiros, M. S., Rieder, C. R. D. M., & Hutz, M. H. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.23 · Cited by 39
Parkinson’s Disease Pharmacogenomics: New Findings and Perspectives
Schuh, A. F. S., Rieder, C. R. D. M., & Hutz, M. H. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.93 · Cited by 38
Influence of Genetic, Biological and Pharmacological Factors on Levodopa Dose in Parkinson’s Disease
Altmann, V., Schuh, A. F. S., Rieck, M., Callegari-Jacques, S. M., Rieder, C. R. D. M., & Hutz, M. H. (2016) · Pharmacogenomics · doi:10.2217/pgs.15.183 · Cited by 38
Linking F-box protein 7 and parkin to neuronal degeneration in Parkinson’s disease (PD)
Zhou, Z., Sathiyamoorthy, S., Angeles, D. C., & Tan, E. K. (2016) · Molecular Brain · doi:10.1186/s13041-016-0218-2 · Cited by 38
Anticholinergic burden in Parkinson’s disease inpatients
Lertxundi, U., Isla, A., Solinís, M. Á., Domingo‐Echaburu, S., Hernandez, R., Peral‐Aguirregoitia, J., & Medrano, J. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1919-7 · Cited by 37
Genome Wide Assessment of Young Onset Parkinson’s Disease from Finland
Hernandez, D. G., Nalls, M. A., Ylikotila, P., Keller, M. F., Hardy, J., Majamaa, K., & Singleton, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041859 · Cited by 35
Whole-exome sequencing of 228 patients with sporadic Parkinson’s disease
Sandor, C., Honti, F., Haerty, W., Szewczyk‐Królikowski, K., Tomlinson, P. R., Evetts, S., Millin, S., Keane, T., McCarthy, S., Durbin, R. M., et al. (2017) · Scientific Reports · doi:10.1038/srep41188 · Cited by 35
Advances in understanding genomic markers and pharmacogenetics of Parkinson’s disease
Jiménez‐Jiménez, F. J., Alonso‐Navarro, H., García‐Martín, E., & Agúndez, J. A. G. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1158250 · Cited by 34
Opportunities in pharmacogenomics for the treatment of Alzheimer’s disease
Cacabelos, R., Torrellas, C., & Carrera, I. (2015) · Future Neurology · doi:10.2217/fnl.15.12 · Cited by 33
Self-citationSchuh, A. F. S., Altmann, V., Rieck, M., Tovo‐Rodrigues, L., Monte, T. L., Callegari-Jacques, S. M., Medeiros, M. S., Rieder, C. R. D. M., & Hutz, M. H. (2013) · The Pharmacogenomics Journal · doi:10.1038/tpj.2013.37 · Cited by 33
Bhidayasiri, R., Hattori, N., Jeon, B., Chen, R., Lee, M. K., Bajwa, J. A., Mok, V., Zhang, B., Syamsudin, T., Tan, L. C. S., et al. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1088783 · Cited by 33
Ahmed, S. S. S. J., Husain, R. S. A., Kumar, S., & Ramakrishnan, V. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.07.041 · Cited by 32
Zhang, M., Mu, H., Shang, Z., Kang, K., Lv, H., Duan, L., Li, J., Chen, X., Teng, Y., Jiang, Y., et al. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.11.004 · Cited by 32
Monoamine transporter contributions to l-DOPA effects in hemi-parkinsonian rats
Conti, M. M., Meadows, S. M., Melikhov-Sosin, M., Lindenbach, D., Hallmark, J., Werner, D. F., & Bishop, C. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.07.025 · Cited by 30
Zhang, Z., Du, X., Xu, H., Xie, J., & Jiang, H. F. (2015) · European Journal of Neuroscience · doi:10.1111/ejn.13012 · Cited by 26
Levandis, G., Balestra, B., Siani, F., Rizzo, V., Ghezzi, C., Ambrosi, G., Cerri, S., Bonizzi, A., Vicini, R., Vairetti, M., et al. (2015) · Neurogastroenterology & Motility · doi:10.1111/nmo.12691 · Cited by 26
The peripheral noradrenergic terminal as possible site of action of salsolinol as prolactoliberin
Székács, D., Bodnár, I., Mravec, B., Květňanský, R., Vizi, E. S., Nagy, G. M., & Fekete, M. I. K. (2006) · Neurochemistry International · doi:10.1016/j.neuint.2006.10.001 · Cited by 24
Association of DYRK1A polymorphisms with sporadic Parkinson’s disease in Chinese Han population
Cen, L., Xiao, Y., Wei, L., Mo, M., Chen, X. '., Li, S., Yang, X., Huang, Q., Qu, S., Pei, Z., et al. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.08.022 · Cited by 24
Serum prolactin levels in Parkinson's disease and multiple system atrophy
Winkler, A. S., Landau, S., & Chaudhuri, К. R. (2002) · Clinical Autonomic Research · doi:10.1007/s10286-002-0025-y · Cited by 22
Cavalcanti, J. R. L. D. P., de Pontes, A. L. B., Fiuza, F. P., Silva, K. D. A., Gúzen, F. P., Lucena, E. E. D. S., do Nascimento, E. S., Cavalcante, J. C., Costa, M. S. M. O., Engelberth, R. C. G. J., et al. (2016) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2016.05.010 · Cited by 21
Professional ethics in complementary and alternative medicines in management of Parkinson’s disease
Kim, H. J., Jeon, B., & Chung, S. J. (2016) · Journal of Parkinson s Disease · doi:10.3233/jpd-160890 · Cited by 20
Pharmacogenetic Considerations in the Treatment of Parkinson’s Disease
Kurzawski, M., Białecka, M. A., & Droździk, M. (2015) · Neurodegenerative Disease Management · doi:10.2217/nmt.14.38 · Cited by 19
SNCA rs356182 variant increases risk of sporadic Parkinson's disease in ethnic Chinese
Cheng, L., Wang, L., Li, N., Yu, W.-J., Sun, X., Li, J., Zhou, D., & Peng, R. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.07.032 · Cited by 19
Gastrointestinal complications in newly diagnosed Parkinson’s disease: A case-control study
Owolabi, L. F., Samaila, A., & Sunmonu, T. (2014) · Tropical Gastroenterology · doi:10.7869/tg.221 · Cited by 19
Buhlman, L. M. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.06.008 · Cited by 18
Phenome-based gene discovery provides information about Parkinson’s disease drug targets
Chen, Y., & Xu, R. (2016) · BMC Genomics · doi:10.1186/s12864-016-2820-1 · Cited by 18
Haaxma, C. A., Horstink, M. W. I. M., Zijlmans, J. C. M., Lemmens, W. A. J. G., Bloem, B. R., & Borm, G. F. (2015) · Journal of Parkinson s Disease · doi:10.3233/jpd-150532 · Cited by 16
Mo, M., Huang, W. Y., Sun, C., Zhang, L., Cen, L., Xiao, Y., Li, G.-F., Yang, X., Qu, S., & Xu, P. (2016) · Chinese Medical Journal · doi:10.4103/0366-6999.180513 · Cited by 16
Transgenic studies on the regulation of the anterior pituitary gland function by the hypothalamus
Wells, S. E., & Murphy, D. (2003) · Frontiers in Neuroendocrinology · doi:10.1016/s0091-3022(02)00103-6 · Cited by 12
Gastrointestinal complications in newly diagnosed Parkinson's disease: A case-control study.
Owolabi, L., Samaila, A. A., & Sunmonu, T. (2014) · PubMed · Cited by 10
L ‐ DOPA attenuates prolactin secretion in response to isolation stress in H olstein steers
Kasuya, E., Yayou, K., & Sutoh, M. (2013) · Animal Science Journal · doi:10.1111/asj.12037 · Cited by 10
Novel gene (TMEM230) linked to Parkinson’s disease
Olszewska, D. A., Fearon, C., & Lynch, T. (2016) · Journal of Clinical Movement Disorders · doi:10.1186/s40734-016-0046-7 · Cited by 7
Biochemical Changes and Cardiovascular Function in Parkinson ’s Disease: Precautionary Notes
Cacabelos, R. (2016) · Clinical & Medical Biochemistry Open Access · doi:10.4172/2471-2663.1000e102 · Cited by 2
Self-citation
Cited by
Analysis of Gut Microbiota in Patients with Parkinson’s Disease
Petrov, V. A., Saltykova, I. V., Zhukova, I. A., Alifirova, V. M., Zhukova, N. G., Dorofeeva, Y. B., Tyakht, A. V., Kovarsky, B. A., Alekseev, D. G., Kostryukova, E. S., et al. (2017) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-017-3700-7 · Cited by 487
Pathological mechanisms and therapeutic strategies for Alzheimer’s disease
Tam, K., & Ju, Y. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.320970 · Cited by 395
Calcium signaling and molecular mechanisms underlying neurodegenerative diseases
Pchitskaya, E., Popugaeva, E., & Bezprozvanny, I. (2018) · Cell Calcium · doi:10.1016/j.ceca.2017.06.008 · Cited by 349
Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs
Charvin, D., Medori, R., Hauser, R. A., & Rascol, O. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.136 · Cited by 287
Zhou, Z.-L., Jia, X.-B., Sun, M.-F., Zhu, Y.-L., Qiao, C.-M., Zhang, B.-P., Zhao, L.-P., Yang, Q., Cui, C., Chen, X., et al. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00719-2 · Cited by 195
Metadata
- Authors
- Cacabelos, R.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-03-04
- Volume
- 18
- Issue
- 3
- Pages
- 551
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2593361577
- Cited by
- 555
- References
- 129
- FWCI
- 25.22
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.